Hikma A strong investment case Our business model and strategy aim to deliver long-term growth for shareholders. Population growth and increased prevalence of chronic diseases are driving demand for better, more accessible healthcare. Hikma is well-positioned to respond to this growing demand. Our business model Our diversified business model enables us to respond to the many opportunities and challenges we face, while delivering value for our patients, employees, shareholders and wider communities. Read more Our strategy Our strategy is to make healthcare more accessible by leveraging our strong foundation, building a portfolio that anticipates future health needs and inspiring and enabling our people. Read more Measuring progress We are delivering our strategy through our three strategic priorities and measuring our performance with relevant key performance indicators (KPIs). Read more Related news Hikma and Winterlight Labs collaborate to develop biomarkers for Schizophrenia patients in MENA 23 November 2021 Hikma Ventures invests in biotechnology company BioSapien Inc., developer of a patented drug-delivery device intended to reduce the system-wide side effects of chemotherapy treatments 11 November 2021 Hikma continues strong 2021 performance and reiterates full year guidance 4 November 2021 Investors Understanding Hikma Back to top Useful links About Products Investors News Careers Contact Worldwide Leadership Stay in touch Subscribe to our newsletter Follow us instagram Created with Sketch. © Hikma Pharmaceuticals PLC 2021 Terms of use Cookie policy Disclaimer Privacy policy Community guidelines Our website uses cookies to improve your experience. Some of the cookies we use are essential for parts of our website to operate. By using our website without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Hikma Key financial data $ million 1H21 1H20 Change Constant currency change Revenue 1,216 1,132 7% 7% Core revenue 1,216 1,132 7% 7% Gross profit 616 577 7% 7% Core gross profit 616 577 7% 7% Operating profit 326 297 10% 15% Core operating profit 309 284 9% 15% EBITDA 358 328 9% 14% Core EBITDA 358 328 9% 14% Profit attributable to shareholders 248 212 17% 26% Core profit attributable to shareholders 223 205 9% 18% Basic earnings per share (cents) 107.4 87.6 23% 32% Core basic earnings per share (cents) 96.5 85.3 13% 23% Interim dividend per share (cents) 18.0 16.0 13% - Cash flow from operating activities 224 292 (23)% - Investors Financial information Back to top Useful links About Products Investors News Careers Contact Worldwide Leadership Stay in touch Subscribe to our newsletter Follow us instagram Created with Sketch. © Hikma Pharmaceuticals PLC 2021 Terms of use Cookie policy Disclaimer Privacy policy Community guidelines Our website uses cookies to improve your experience. Some of the cookies we use are essential for parts of our website to operate. By using our website without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.